US5780587A
(en)
*
|
1990-08-24 |
1998-07-14 |
President And Fellows Of Harvard College |
Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
|
US6303567B1
(en)
*
|
1995-03-14 |
2001-10-16 |
Praecis Pharmaceuticals, Inc . |
Modulators of β-amyloid peptide aggregation comprising D-amino acids
|
CA2214247C
(en)
*
|
1995-03-14 |
2004-02-10 |
Praecis Pharmaceuticals Incorporated |
Modulators of amyloid aggregation
|
US5948763A
(en)
*
|
1995-06-07 |
1999-09-07 |
New York University |
Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
|
US5985242A
(en)
*
|
1995-10-27 |
1999-11-16 |
Praecis Pharmaceuticals, Inc. |
Modulators of β-amyloid peptide aggregation comprising D-amino acids
|
US6277826B1
(en)
|
1996-08-27 |
2001-08-21 |
Praecis Pharmaceuticals, Inc. |
Modulators of β-amyloid peptide aggregation comprising D-amino acids
|
AU1072897A
(en)
*
|
1995-12-12 |
1997-07-03 |
Karolinska Innovations Ab |
Peptide binding the klvff-sequence of amyloid beta
|
DK0929574T3
(da)
*
|
1996-08-27 |
2005-10-31 |
Praecis Pharm Inc |
Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
|
US6022859A
(en)
*
|
1996-11-15 |
2000-02-08 |
Wisconsin Alumni Research Foundation |
Inhibitors of β-amyloid toxicity
|
US6172043B1
(en)
*
|
1997-01-10 |
2001-01-09 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
|
US7045531B1
(en)
|
1997-03-11 |
2006-05-16 |
The General Hospital Corporation |
Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
|
AU748768B2
(en)
*
|
1997-03-11 |
2002-06-13 |
General Hospital Corporation, The |
Identification of agents for use in the treatment of Alzheimer's disease
|
DE19725619A1
(de)
*
|
1997-06-17 |
1998-12-24 |
Fraunhofer Ges Forschung |
Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
|
EP1005654B1
(de)
|
1997-08-01 |
2006-04-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten
|
EP1001987B1
(de)
*
|
1997-08-01 |
2010-12-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
|
US6600017B1
(en)
|
1997-08-14 |
2003-07-29 |
The Regents Of The University Of California |
Fluorescent amyloid Aβ peptides and uses thereof
|
US6703015B1
(en)
*
|
1999-09-03 |
2004-03-09 |
Ramot At Tel-Aviv University Ltd. |
Filamentous bacteriophage displaying an β-amyloid epitope
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7799535B1
(en)
*
|
1997-12-09 |
2010-09-21 |
Arch Development Corporation |
Methods for identifying factors that control the folding of amyloid proteins of diverse origin
|
AU2600499A
(en)
*
|
1998-02-13 |
1999-08-30 |
Arch Development Corporation |
Methods and compositions comprising the use of blocked b-amyloid peptide
|
US6638711B1
(en)
|
1999-04-29 |
2003-10-28 |
The General Hospital Corporation |
Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
|
US6323218B1
(en)
|
1998-03-11 |
2001-11-27 |
The General Hospital Corporation |
Agents for use in the treatment of Alzheimer's disease
|
US6211149B1
(en)
*
|
1998-08-03 |
2001-04-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors of formation of protease resistant prion protein
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US7122620B1
(en)
*
|
1998-05-27 |
2006-10-17 |
Medical Research Services And Development Ltd. |
Haptotactic peptides
|
WO2000052048A1
(en)
|
1999-03-04 |
2000-09-08 |
Praecis Pharmaceuticals Incorporated |
Modulators of beta-amyloid peptide aggregation comprising d-amino acids
|
EP1870419A3
(de)
*
|
1999-03-04 |
2008-01-02 |
Praecis Pharmaceuticals Incorporated |
Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren
|
US7060670B1
(en)
*
|
1999-05-05 |
2006-06-13 |
Neurochem (International) Limited |
Stereoselective antifibrillogenic peptides and peptidomimetics thereof
|
WO2000068263A2
(en)
*
|
1999-05-05 |
2000-11-16 |
Neurochem, Inc. |
Stereoselective antifibrillogenic peptides and peptidomimetics thereof
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
EP1187920A2
(de)
*
|
1999-06-09 |
2002-03-20 |
Arch Development Corporation |
Rekombinante prionänhliche gene, proteine, materialien und verfahren davon
|
AUPQ180499A0
(en)
*
|
1999-07-23 |
1999-08-19 |
Biomolecular Research Institute Limited |
Beta-amyloid peptide inhibitors
|
AU6234700A
(en)
*
|
1999-07-27 |
2001-02-13 |
Abgenix, Inc. |
Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
|
GB9917725D0
(en)
*
|
1999-07-28 |
1999-09-29 |
Medical Res Council |
Peptides
|
GB9917724D0
(en)
|
1999-07-28 |
1999-09-29 |
Medical Res Council |
Peptides
|
PL354122A1
(en)
*
|
1999-08-09 |
2003-12-29 |
Tripep Abtripep Ab |
Pharmaceutical compositions containing tripeptides
|
US6689753B1
(en)
*
|
1999-11-05 |
2004-02-10 |
Axonyx, Inc. |
β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
|
IL149392A0
(en)
*
|
1999-11-05 |
2002-11-10 |
Axonyx Inc |
PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
|
US20070135337A2
(en)
*
|
1999-11-29 |
2007-06-14 |
Neurochem (International) Limited |
Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
|
US20020094335A1
(en)
*
|
1999-11-29 |
2002-07-18 |
Robert Chalifour |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
AU3808801A
(en)
*
|
2000-02-11 |
2001-08-20 |
Praecis Pharmaceuticals Incorporated |
Methods for enhancing the bioavailability of a drug
|
MEP30408A
(en)
*
|
2000-02-21 |
2010-10-10 |
Pharmexa As |
Novel method for down-regulation of amyloid
|
KR20080017471A
(ko)
*
|
2000-02-21 |
2008-02-26 |
파멕사 에이/에스 |
아밀로이드의 하향-조절을 위한 신규한 방법
|
US20070179197A1
(en)
*
|
2000-05-01 |
2007-08-02 |
Accera, Inc. |
Compositions and methods for improving or preserving brain function
|
US6835750B1
(en)
|
2000-05-01 |
2004-12-28 |
Accera, Inc. |
Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
|
EP1292294B1
(de)
|
2000-05-01 |
2009-03-18 |
Accera, Inc. |
Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
|
AU2007200047B2
(en)
*
|
2000-07-07 |
2009-11-26 |
Bioarctic Neuroscience Ab |
Prevention and treatment of Alzheimer's disease
|
JP5362164B2
(ja)
|
2000-07-07 |
2013-12-11 |
バイオアークティック ニューロサイエンス アーベー |
アルツハイマー病の予防及び治療
|
US6472436B1
(en)
*
|
2000-07-17 |
2002-10-29 |
The Salk Institute For Biological Studies |
Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
|
US20030044413A1
(en)
*
|
2000-08-15 |
2003-03-06 |
Regents Of The University Of Minnesota |
Methods of limiting apoptosis of cells
|
AU2002212471A1
(en)
*
|
2000-11-01 |
2002-05-15 |
Insight Biotechnology Limited |
Peptides for use in the treatment of alzheimer's disease
|
GB0028710D0
(en)
*
|
2000-11-24 |
2001-01-10 |
Isis Innovation |
Mixed fibrils
|
WO2002042462A2
(en)
*
|
2000-11-27 |
2002-05-30 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
DE10101430B4
(de)
*
|
2001-01-13 |
2008-10-02 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Lösliche cyclische Analoga zur Modulation der Amyloidogenese
|
US7320793B2
(en)
|
2001-01-19 |
2008-01-22 |
Cytos Biotechnology Ag |
Molecular antigen array
|
AU2002254328A1
(en)
*
|
2001-03-20 |
2002-10-03 |
University Of Chicago |
Inhibitors and disassemblers of fibrillogenesis
|
JP2002346015A
(ja)
*
|
2001-05-28 |
2002-12-03 |
Hiroaki Yoshiike |
スイング診断装置
|
JP4235544B2
(ja)
|
2001-05-31 |
2009-03-11 |
アドライフ インコーポレーティッド |
欠陥折畳み蛋白質センサー方法
|
WO2003006043A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Massachusetts Institute Of Technology |
Surfactant peptide nanostructures, and uses thereof
|
MY144532A
(en)
*
|
2001-08-20 |
2011-09-30 |
Lundbeck & Co As H |
Novel method for down-regulation of amyloid
|
US6593455B2
(en)
*
|
2001-08-24 |
2003-07-15 |
Tripep Ab |
Tripeptide amides that block viral infectivity and methods of use thereof
|
US20030082191A1
(en)
*
|
2001-08-29 |
2003-05-01 |
Poduslo Joseph F. |
Treatment for central nervous system disorders
|
WO2003025156A2
(en)
*
|
2001-09-18 |
2003-03-27 |
Affinium Pharmaceuticals, Inc. |
Methods and apparatuses for purification
|
WO2003024995A1
(en)
*
|
2001-09-19 |
2003-03-27 |
Tripep Ab |
Molecules that block viral infectivity and methods of use thereof
|
US20040038861A1
(en)
*
|
2001-11-26 |
2004-02-26 |
Cooper Garth J. S. |
Methods and compositions for normalizing lipid levels in mammalian tissues
|
WO2003051374A2
(en)
*
|
2001-12-17 |
2003-06-26 |
New York State Office Of Mental Health |
SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
|
AU2002360696A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Ilex Oncology, Inc. |
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
|
WO2003063880A1
(en)
*
|
2002-01-29 |
2003-08-07 |
Protemix Corporation Limited |
Disruption of islet amyloid by polycyclic compounds
|
US20040052928A1
(en)
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
AU2004203461B2
(en)
*
|
2002-01-31 |
2009-09-03 |
Tel Aviv University Future Technology Development L.P. |
Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
|
WO2005000193A2
(en)
|
2003-06-30 |
2005-01-06 |
Tel Aviv University Future Technology Development L.P. |
Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
|
EP1820806A1
(de)
*
|
2006-02-16 |
2007-08-22 |
Crossbeta Biosciences B.V. |
Affinitätsbereiche
|
WO2003071269A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Affinium Pharmaceuticals, Inc. |
Methods and apparatuses for characterizing stability of biological molecules
|
TW200416037A
(en)
*
|
2002-02-20 |
2004-09-01 |
Kanegafuchi Chemical Ind |
Process for producing hydrophobic glycyrrhiza extract with high qualities
|
US20050079526A1
(en)
*
|
2002-02-20 |
2005-04-14 |
Affinium Pharmaceuticals, Inc. |
Methods and apparatuses for characterizing refolding and aggregation of biological molecules
|
US20050148650A1
(en)
|
2002-03-01 |
2005-07-07 |
Shigenori Ohkawa |
Antidepressant
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
EP1490087A4
(de)
*
|
2002-03-22 |
2007-07-11 |
Univ Emory |
Sich selbst zusammensetzende strukturen auf peptidbasis und verfahren zur kontrolle der selbstzusammensetzung dieser strukturen
|
WO2003087834A2
(en)
*
|
2002-04-08 |
2003-10-23 |
Affinium Pharmaceuticals, Inc. |
High throughput analysis of recombinant proteins in multi-well plates
|
US6846640B2
(en)
*
|
2002-04-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
|
DE10221052A1
(de)
*
|
2002-05-10 |
2003-12-04 |
Transmit Technologietransfer |
Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
|
EP1380290A1
(de)
|
2002-07-09 |
2004-01-14 |
Universitair Medisch Centrum Utrecht |
Cross-Beta-Strukturweg und seine therapeutische Relevanz
|
US20070003552A1
(en)
*
|
2002-07-09 |
2007-01-04 |
Gebbink Martijn F B |
Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
|
EP1523499A2
(de)
*
|
2002-07-24 |
2005-04-20 |
Innogenetics N.V. |
Fragmente von beta-amyloid als angriffspunkt einer impfung gegen alzheimersche krankheit
|
US20040121445A1
(en)
*
|
2002-07-31 |
2004-06-24 |
Fabien Marino |
Cell cultures
|
US7345022B2
(en)
|
2002-09-19 |
2008-03-18 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Anti-fibril peptides
|
US20050096319A1
(en)
*
|
2003-02-21 |
2005-05-05 |
Balzarini Jan M.R. |
Identification of compounds that inhibit replication of human immunodeficiency virus
|
US20040180893A1
(en)
*
|
2003-02-21 |
2004-09-16 |
Balzarini Jan Maria Rene |
Identification of compounds that inhibit replication of human immunodeficiency virus
|
CN1756554A
(zh)
*
|
2003-03-06 |
2006-04-05 |
艾克塞拉公司 |
新的化学实体和它们用于治疗代谢障碍的方法
|
US7189694B2
(en)
*
|
2003-04-18 |
2007-03-13 |
University Of Florida Research Foundation, Inc. |
Inhibitors of autophosphorylation protein kinases
|
CA2522460A1
(en)
*
|
2003-04-30 |
2004-11-11 |
Applied Research Systems Ars Holding N.V. |
Beta-amyloid inhibitors and use thereof
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
JP4888876B2
(ja)
*
|
2003-06-13 |
2012-02-29 |
田平 武 |
アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
|
CA2540407A1
(en)
|
2003-09-25 |
2005-03-31 |
Tel Aviv University Future Technology Development L.P. |
Compositions and methods using same for treating amyloid-associated diseases
|
WO2005059100A2
(en)
*
|
2003-12-12 |
2005-06-30 |
New York University |
Methods and compositions relating to cystatin c
|
AU2004311796A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Centocor, Inc. |
Novel recombinant proteins with N-terminal free thiol
|
CN1980694B
(zh)
|
2004-05-12 |
2012-09-26 |
布赖汉姆妇女医院有限公司 |
凝溶胶蛋白治疗感染的用途
|
SE0401601D0
(sv)
|
2004-06-21 |
2004-06-21 |
Bioarctic Neuroscience Ab |
Protofibril specific antibodies and uses thereof
|
AU2005275009B2
(en)
*
|
2004-07-16 |
2011-12-08 |
Trustees Of Tufts College |
Apolipoprotein A1 mimetics and uses thereof
|
US20060057671A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Orser Cindy S |
Immobilized probes and methods of detecting conformationally altered prion proteins
|
US7161443B2
(en)
*
|
2004-09-30 |
2007-01-09 |
Broadcom Corporation |
Temperature compensated crystal oscillator
|
PE20061329A1
(es)
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
Anticuerpos ab humanizados para mejorar la cognicion
|
WO2006066049A2
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20090202980A1
(en)
*
|
2005-03-21 |
2009-08-13 |
Crossbeta Biosciences B.V. |
Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
|
US9335331B2
(en)
*
|
2005-04-11 |
2016-05-10 |
Cornell Research Foundation, Inc. |
Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
|
US20060252775A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Henderson Samuel T |
Methods for reducing levels of disease associated proteins
|
EP1915144A4
(de)
*
|
2005-06-20 |
2009-08-19 |
Accera Inc |
Verfahren zur reduzierung von oxidativen schäden und zur verbesserung der mitochondrien-effizienz
|
EP1906995A2
(de)
*
|
2005-07-13 |
2008-04-09 |
Crossbeta Biosciences B.V. |
Adjuvation durch kreuzstruktur
|
EP1910844B1
(de)
*
|
2005-07-13 |
2012-04-18 |
Crossbeta Biosciences B.V. |
Cross-beta-struktur-bindende verbindungen
|
US8114832B2
(en)
*
|
2005-07-13 |
2012-02-14 |
Crossbeta Biosciences B.V. |
Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
|
WO2007020888A1
(ja)
|
2005-08-12 |
2007-02-22 |
Takeda Pharmaceutical Company Limited |
脳・神経細胞保護剤および睡眠障害治療薬
|
US20100130416A1
(en)
*
|
2005-11-10 |
2010-05-27 |
Archer Pharmaceuticals, Inc. |
Modulation of angiogenesis by a-beta peptide fragments
|
KR20080095836A
(ko)
|
2005-11-10 |
2008-10-29 |
로스캄프 리서치 엘엘씨 |
A―베타 펩티드 단편에 의한 혈관형성의 조정
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
RU2551782C2
(ru)
|
2005-12-12 |
2015-05-27 |
Ац Иммуне Са |
Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
BRPI0620125B1
(pt)
*
|
2005-12-22 |
2022-05-17 |
Vrije Universiteit Brussel |
Método para regulação de redução da função biológica de uma proteína, e método para isolar uma proteína de uma amostra
|
JP5888832B2
(ja)
*
|
2005-12-22 |
2016-03-22 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー)Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw(Vib Vzw) |
タンパク質干渉を媒介する手段および方法
|
US8198094B2
(en)
|
2006-03-15 |
2012-06-12 |
The Brigham And Women's Hospital, Inc. |
Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
|
JP5033868B2
(ja)
*
|
2006-03-23 |
2012-09-26 |
バイオアークティック ニューロサイエンス アーベー |
改良型プロトフィブリル選択的抗体及びその使用
|
EP2001293B9
(de)
|
2006-04-03 |
2019-04-17 |
Accera, Inc. |
Verwendung ketogener verbindungen zur behandlung altersbedingter gedächtnisschwächen
|
TWI334784B
(en)
*
|
2006-04-14 |
2010-12-21 |
Buck Inst For Age Res |
Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
DE112007001030T5
(de)
*
|
2006-04-28 |
2009-02-26 |
Kagoshima University |
Amyloid-ß-Fibrillogenese-inhibierendes Peptid
|
WO2008013859A2
(en)
*
|
2006-07-28 |
2008-01-31 |
Adlyfe, Inc. |
Peptide probes for diagnostics and therapeutics
|
US8188046B2
(en)
*
|
2006-10-16 |
2012-05-29 |
University Of South Florida |
Amyloid beta peptides and methods of use
|
EP2121633A2
(de)
|
2007-02-12 |
2009-11-25 |
Merck & Co., Inc. |
Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden
|
WO2008106657A2
(en)
*
|
2007-03-01 |
2008-09-04 |
Intezyne Technologies, Inc. |
Encapsulated amyloid-beta peptides
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
JP5568008B2
(ja)
*
|
2007-06-27 |
2014-08-06 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ペプチドチロシナーゼインヒビターおよびその使用
|
EP2173370B1
(de)
*
|
2007-06-27 |
2015-10-21 |
The Board of Trustees of the Leland Stanford Junior University |
Oligopeptid-tyrosinase-inhibitoren und ihre verwendungen
|
WO2009005783A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Blanchette Rockefeller Neurosciences Institute |
Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
|
PL2182983T3
(pl)
|
2007-07-27 |
2014-10-31 |
Janssen Alzheimer Immunotherap |
Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
|
ES2556537T3
(es)
|
2007-07-31 |
2016-01-18 |
Accera, Inc. |
Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
WO2009059239A2
(en)
*
|
2007-11-02 |
2009-05-07 |
Mayo Foundation For Medical Education And Research |
REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
|
EP2058001A1
(de)
*
|
2007-11-08 |
2009-05-13 |
Crossbeta Biosciences B.V. |
Steigerung der Immunogenizität von Antigenen
|
EP2058000A1
(de)
*
|
2007-11-08 |
2009-05-13 |
Crossbeta Biosciences B.V. |
Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
|
PL2708603T3
(pl)
|
2008-01-25 |
2017-12-29 |
Beth Israel Deaconess Medical Ct Inc |
Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek
|
US8852874B2
(en)
*
|
2008-02-29 |
2014-10-07 |
Baxter International Inc. |
Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro
|
US8105809B2
(en)
*
|
2008-07-03 |
2012-01-31 |
Accera, Inc. |
Enzymatic synthesis of acetoacetate esters and derivatives
|
US9125881B2
(en)
*
|
2008-07-03 |
2015-09-08 |
Accera, Inc. |
Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
WO2010091253A1
(en)
|
2009-02-06 |
2010-08-12 |
Women & Infants' Hospital Of Rhode Island |
Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
|
WO2010104194A1
(en)
|
2009-03-10 |
2010-09-16 |
Takeda Pharmaceutical Company Limited |
Benzofuran derivatives
|
US9023767B2
(en)
*
|
2009-05-07 |
2015-05-05 |
Memorial Sloan-Kettering Cancer Center |
γ-Secretase substrates and methods of use
|
JP5554528B2
(ja)
*
|
2009-09-08 |
2014-07-23 |
国立大学法人 岡山大学 |
新規アミロイドβ凝集体結合性ペプチドおよび新規アミロイドβ凝集体結合性ペプチドを用いたアミロイド病の検査方法
|
CN103502466A
(zh)
|
2010-09-07 |
2014-01-08 |
斯隆-凯特林纪念癌症中心 |
用于γ-分泌酶测定的方法和组合物
|
EP2625170A1
(de)
|
2010-10-07 |
2013-08-14 |
Takeda Pharmaceutical Company Limited |
1,4-oxazepanderivate
|
TW201225972A
(en)
|
2010-11-15 |
2012-07-01 |
Univ Ramot |
Dipeptide analogs for treating conditions associated with amyloid fibril formation
|
WO2013021353A1
(en)
|
2011-08-11 |
2013-02-14 |
Bar-Ilan University |
Surface modified proteinaceous spherical particles and uses thereof
|
SG2014010417A
(en)
|
2011-10-07 |
2014-06-27 |
Takeda Pharmaceutical |
1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
|
ES2938886T3
(es)
|
2012-04-05 |
2023-04-17 |
Priavoid Gmbh |
Procedimiento para el tratamiento de sangre, productos sanguíneos y órganos
|
CN107652356A
(zh)
|
2012-04-05 |
2018-02-02 |
于利希研究中心有限公司 |
包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
|
DE102012102998B4
(de)
*
|
2012-04-05 |
2013-12-05 |
Forschungszentrum Jülich GmbH |
Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
|
KR20150022753A
(ko)
*
|
2012-04-26 |
2015-03-04 |
아미렉스 파마슈티컬즈, 인코포레이티드 |
베타-아밀로이드의 체외 감소를 위한 신규 조성물 및 이의 제조 방법
|
JP6249952B2
(ja)
|
2012-10-16 |
2017-12-20 |
武田薬品工業株式会社 |
複素環化合物
|
MX2015007495A
(es)
|
2012-12-11 |
2015-09-04 |
Takeda Pharmaceutical |
Compuesto heterociclico.
|
JP5804463B2
(ja)
|
2012-12-27 |
2015-11-04 |
国立研究開発法人科学技術振興機構 |
環状ペプチド及びこれを含有する医薬
|
US20140280367A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Sap Ag |
Silo-aware databases
|
EP2982670B1
(de)
|
2013-04-04 |
2018-11-07 |
Takeda Pharmaceutical Company Limited |
Heterocyclische verbindung
|
WO2014163161A1
(ja)
|
2013-04-04 |
2014-10-09 |
武田薬品工業株式会社 |
複素環化合物
|
DE102014003262A1
(de)
|
2014-03-12 |
2015-09-17 |
Forschungszentrum Jülich GmbH |
Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
|
US10597696B2
(en)
|
2013-09-18 |
2020-03-24 |
University Of Notre Dame Du Lac |
Detection of Niemann-Pick disease comprising detection of lysozyme and cathepsins
|
DK3049099T3
(da)
|
2013-09-26 |
2020-09-21 |
Priavoid Gmbh |
Amyloid-beta-bindende peptider og anvendelse deraf til terapi og diagnosticering af alzheimers demens
|
EP3152198B1
(de)
|
2014-06-09 |
2019-02-27 |
Takeda Pharmaceutical Company Limited |
Radioaktiv markierte verbindungen
|
MA40224B1
(fr)
|
2014-07-10 |
2021-05-31 |
Eisai R&D Man Co Ltd |
Anticorps se liant aux protofibrilles ass améliorés
|
GB201414038D0
(en)
*
|
2014-08-07 |
2014-09-24 |
Univ Sussex The |
Alzheimer's disease
|
CN108350052A
(zh)
|
2015-11-09 |
2018-07-31 |
英属哥伦比亚大学 |
淀粉样蛋白β中间区域中的表位及其构象选择性抗体
|
JP7452829B2
(ja)
|
2015-11-09 |
2024-03-19 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
アミロイドベータのエピトープおよびそれに対する抗体
|
HUE057696T2
(hu)
|
2016-02-04 |
2022-05-28 |
Takeda Pharmaceuticals Co |
Helyettesített piperidin vegyület és alkalmazása
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
JP6957598B2
(ja)
|
2017-03-08 |
2021-11-02 |
武田薬品工業株式会社 |
置換ピロリジン化合物およびその用途
|
CN110621688A
(zh)
|
2017-05-09 |
2019-12-27 |
非营利性组织佛兰芒综合大学生物技术研究所 |
用于治疗细菌感染的手段和方法
|
EP3660003B1
(de)
|
2017-07-28 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Heterocyclische verbindung
|
JP7189140B2
(ja)
|
2017-08-03 |
2022-12-13 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
EP3774800A1
(de)
|
2018-03-28 |
2021-02-17 |
Takeda Pharmaceutical Company Limited |
Heterocyclische verbindung und verwendung davon
|
EP3816154A4
(de)
|
2018-06-29 |
2022-03-30 |
Takeda Pharmaceutical Company Limited |
Heterocyclische verbindung und anwendung davon
|
EP3915638A4
(de)
|
2019-01-24 |
2022-10-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclische verbindung und verwendung davon
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
MX2022003018A
(es)
|
2019-09-13 |
2022-06-14 |
Takeda Pharmaceuticals Co |
Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
|
CA3154320A1
(en)
|
2019-09-13 |
2021-03-18 |
Takeda Pharmaceutical Company Limited |
Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
|
JP2021050161A
(ja)
|
2019-09-25 |
2021-04-01 |
武田薬品工業株式会社 |
複素環化合物及びその用途
|
JP2023550654A
(ja)
|
2020-11-25 |
2023-12-04 |
セージ セラピューティクス, インコーポレイテッド |
神経変性障害の治療のためのcyp46a1阻害剤としての4-フルオロ-(4-(4-ベンジル)ピペリジン-1-イル)(2-(ピリミジン-4-イル)ピリジン-3-イル)メタノン誘導体および類似化合物
|
WO2022190060A1
(en)
|
2021-03-12 |
2022-09-15 |
Takeda Pharmaceutical Company Limited |
An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
|
TW202304437A
(zh)
|
2021-04-02 |
2023-02-01 |
日商武田藥品工業股份有限公司 |
食慾激素2受體促效劑對於手術後復原的用途
|